5 research outputs found
Predicted trajectories of mean √CD4 cell counts since HIV diagnosis according to blip status during the period of HIV control (81 HIV controllers, 1668 CD4 measurements).
<p>Predicted trajectories of mean √CD4 cell counts since HIV diagnosis according to blip status during the period of HIV control (81 HIV controllers, 1668 CD4 measurements).</p
Comparison of baseline characteristics between HIV controllers and patients enrolled in the ANRS SEROCO Cohort and still alive in 2007.
<p>Data are median [IQR] or n (%);</p><p>*SSA/C  =  SubSaharan Africans or Caribbeans;</p><p>**Following HIV diagnosis.</p
Predicted trajectories of mean √CD4 cell counts since HIV diagnosis according to blip status in the last five years of control (always ≤50 copies vs. blips within 50–400 and blips >400 copies/mL) (81 HIV controllers, 1668 CD4 measurements).
<p>Predicted trajectories of mean √CD4 cell counts since HIV diagnosis according to blip status in the last five years of control (always ≤50 copies vs. blips within 50–400 and blips >400 copies/mL) (81 HIV controllers, 1668 CD4 measurements).</p
Characteristics at baseline and at cART initiation in 34 elite Controllers (ECs) and 478 chronically viremic (VIRs) patients from the ANRS COPANA Cohort.
<p>Data are median [IQR] or n (%);</p><p>According to own cohort’s definitions of ECs;</p><p>SSA/Car/BA = Sub-Saharan African, Caribbean or African-American origin.</p
Estimated CD4 cell count dynamics in viremic patients (VIRs: n = 478) and elite controllers (ECs: n = 34) in mixed-effect linear models (mean CD4 T cells gain after 12 months of cART was significantly lower in ECs than in VIRs (p = 0.048)).
<p>Estimated CD4 cell count dynamics in viremic patients (VIRs: n = 478) and elite controllers (ECs: n = 34) in mixed-effect linear models (mean CD4 T cells gain after 12 months of cART was significantly lower in ECs than in VIRs (p = 0.048)).</p